摘要
替考拉宁是继万古霉素后上市的治疗金黄色葡萄球菌(SAU)感染的新型糖肽类抗生素,研究已发现替考拉宁安全性较万古霉素高,尤其在肾毒性方面,所以未对其开展常规血药浓度监测。但近年来研究发现,替考拉宁临床应用个体差异较大,建议用药时行血药浓度监测。而国内替考拉宁的血药浓度监测研究较少,临床应用经验不足。本文从替考拉宁药代动力学特点、血药浓度与疗效和不良反应的相关性、血药浓度影响因素等方面展开综述,为替考拉宁血药浓度监测及应用提供参考。
Teicoplanin is a new glycopeptide antibiotic marketed after vancomycin for the treatment of Staphylo coccus aureus(SAU)infection.Previous studies have shown that teicoplanin is safer than vancomycin,especially in the nephrotoxicity,so the routine serum concentration monitoring was not performed in the clinical application of teico planin.In recent years,it has been found that the individual differences frequently appeared in the clinical application of teicoplanin,and thus it has been suggested that the serum concentration monitoring should be carried out in its clinical application.However,the domestic studies on the serum teicoplanin concentration monitoring are rarely conducted,and its clinical application experience is insufficient in China.This paper reviews the therapeutic drug monitoring of teico planin,in terms of the pharmacokinetic characteristics of teicoplanin,the correlation between the blood concentration with the efficacy and adverse reactions,and the factors influencing the blood concentration of teicoplanin,so as to pro vide a reference for the therapeutic drug monitoring and the rational clinical application of teicoplanin.
作者
李红莲
张峻
卢珊珊
LI Hong-lian;ZHANG Jun;LU Shan-shan(Department of Clinical Pharmacy,the First Affiliated Hospital of Kunming Medical University,Kunming 650000,China)
出处
《国际药学研究杂志》
CAS
北大核心
2019年第7期492-497,共6页
Journal of International Pharmaceutical Research
基金
云南省医疗卫生单位内设研究机构科研项目(2018NS0152)
关键词
替考拉宁
药物浓度监测
血药谷浓度
teicoplanin
therapeutic drug monitoring
blood trough concentration
